Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept plus dexamethasone intravitreal implant for refractory macular edema
ChiCTR2600124921Phase 4Recruiting
- Sponsor
- Shenzhen University General Hospital
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of conbercept and dexamethasone in Refractory macular edema (RME) (2 arms), sponsored by Shenzhen University General Hospital. Primary endpoints: Best corrected visual acuity (BCVA) and Macular fovea retinal thickness (CMT). Started May 2026; status: recruiting.
02
Drugs
conberceptdexamethasone
03
Conditions
Refractory macular edema (RME)
Beyond the preview
Go deeper on ChiCTR2600124921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124921.